Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

By S. Hanauer, C. Wagner, M. Bala, L. Mayer, S. Travers, R. Diamond, A. Olson, Warren Bao, P. Rutgeerts. Clinical Gastroenterology and Hepatology, 2004

653 citations recorded by the source corpus.

Subfields: Gastroenterology, Genetics, Immunology

View Paper: https://www.semanticscholar.org/paper/12370552c97283129d2069021fcf57b636ae5dfb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. W. Sandborn
2. J. Colombel
3. S. Hanauer
4. G. Lichtenstein
5. B. Feagan
6. P. Rutgeerts
7. Bruce E. Sands
8. S. Ben-Horin

In Immunology

1. W. Sandborn
2. S. Hanauer
3. Stefan Schreiber

Citations in the corpus

• Infliximab for induction and maintenance therapy for ulcerative colitis. (2005, background): “[25] Samples positive for antinuclear antibodies were tested for antibodies against double-stranded DNA.”
• Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial (2008, background): “Antibodies to infliximab, n (%)** Absent 91 (57) 88 (59) Indeterminate†† 8 (6)‡‡ 12 (8) Present 60 (38)‡‡ 50 (33) Concomitant medication, n (%) Steroids§§ 73 (44) 55 (35) Any immunosuppressive agent 85 (51) 73 (46) 5-aminosalicylates 60 (36) 45 (28) Current smoker, n (%) 56 (34) 55 (35)”
• Review article: loss of response to anti‐TNF treatments in Crohn’s disease (2011, result): “Similarly, a subanalysis of the ACCENT trial of CD patients showed that as early as 2 weeks’ postinfusion, infliximab level in the blood is lower for patients who were ATI+ compared with those who were ATI) (and to those with inconclusive result).(24) In addition to hastened drug clearance, neutrali”